Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3051 - Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation

Date

09 Oct 2016

Session

Poster display

Presenters

Miriam Lobo

Citation

Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385

Authors

M. Lobo1, S. Lopez-Tarruella2, S. Luque3, S. Lizarraga3, P. Rincon3, A. Hernandez3, E. Mendizabal3, O. Bueno4, M. Cebollero5, S. Perez Ramirez2, Y. Jerez2, M.I. Palomero Plaza2, R. Gonzalez del Val2, G. Garcia2, I. Echavarria Diaz-Guardamino2, A. Calin6, J.A. Blanco6, C. Flores Sanchez2, M. Martin2, I. Marquez-Rodas2

Author affiliations

  • 1 Medical Oncology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 3 Gynaecology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 4 Radiology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 5 Pathology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 6 Radiation Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
More

Resources

Abstract 3051

Background

Identifying Breast Cancer (BC) patients with genetic risk reduces the mortality for BC and the prevention of second tumors. In 2010, we implemented a multidisciplinar Heredofamilial Cancer Unit (HFCU). We hypothesized that the creation of this HFCU improved the referral and proper preventive management of patients with BC and genetic risk.

Methods

We retrospectively compared family history record (FHR), referral of patients with high risk to genetic counseling (GC), detection and management of BRCA 1/2 mutated (+) patients, of BC patients diagnosed and treated in our institution before (July 2007-June 2010, first period) and after the HFCU creation (July 2010-June 2013, second period). Main characteristics of BRCA 1/2+ patients were also analyzed.

Results

893 patients from the first period and 902 in the second met inclusion criteria. Mean age at diagnosis was similar in both groups (57.6 vs 57.8y, p NS). 142 patients (15.9%) vs 70 (7.8%) were not analyzable because a lack of complete information to establish the genetic risk (p 

Conclusions

There is a clear improvement in FHR, referral and preventive surgeries in BC patients with genetic risk after the implementation of the HFCU. TNBC predominates in BRCA1+ while luminal in BRCA2 +.

Clinical trial identification

Legal entity responsible for the study

Hospital General Universitario Gregorio Marañon

Funding

Hospital General Universitario Gregorio Marañon

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings